A recent Health Technology Assessment (HTA) report by the United Kingdom’s National Institute for Health and Care Excellence (NICE) concludes that adalimumab, etanercept, and ustekinumab improve the symptoms of psoriasis in children and young people in the short term, but the cost-effectiveness of these medications requires further study.
A recent Health Technology Assessment (HTA) report by the United Kingdom’s National Institute for Health and Care Excellence (NICE) concludes that adalimumab, etanercept, and ustekinumab all improve the symptoms of psoriasis in children and young people in the short term, but because there is such a limited body of evidence on the use of these drugs in children, the effects of biologic therapies later in patients’ lives are unclear, and the cost-effectiveness of these medications requires further study.
NICE researchers, led by Ana Duarte, MD, investigated health-related quality of life (QOL) gains associated with treatment, as well as the number of hospitalizations in children and young people with plaque psoriasis who were using 1 of the 3 biologics approved for use by the United Kingdom’s National Health Service (NHS) for that indication. They found that biological treatments appear to offer some benefits, but may not be cost-effective for the management of psoriasis in children and young people at the willingness-to-pay threshold of £30,000 (approximately $39,735) per quality-adjusted life-year unless an assumption is made that the consequences of biologic treatment long-term in children are the same as those in adults.
The cost-effectiveness analysis considered 3 separate populations:
The report concluded the following:
Finally, the authors advise continued collection of data through registries of biological therapies for individuals aged under 18 years. These data will allow researchers to better understand safety, patterns of treatment switching, impact on comorbidities, and long-term withdrawal rates for these therapies. The uncertainty surrounding the effectiveness of biological treatments in children and young people could be substantially reduced through adequately powered randomized clinical trials, which are currently lacking.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.